27898506|t|Estimation of populational 24-h urinary sodium and potassium excretion from spot urine samples: evaluation of four formulas in a large national representative population
27898506|a|The aim of this study was to assess the validity of the estimation of 24-h urinary sodium (UNa) and urinary potassium (UK) excretion obtained through four formulae based on occasional urine samples. We analysed 2399 individuals (51% females) aged 18 to 96 years representatives of Portuguese population. Tanaka, Kawasaki, INTERSALT and NHANES formulae were used to predict 24-h UNa and UK excretion s from spot morning urinary samples (OUrS). We compared it with validated real 24-h urine samples (VUrS) (24-h UNa: 4052 ± 1432 mg/ day, 24-h UK = 2928 ± 1004 mg/ day). We compared observed vs. estimated measurements by examining bias (observed minus predicted UNa and UK), the correlation and intraclass correlation (ICC) coefficients between measurements, and Bland-Altman plots. We analysed the differences between observed and estimated Na and K excretion across subgroups defined by quintiles of observed Na and K excretion and subgroups defined hypertension status and control. The area under the ROC curve was used to assess the discriminatory capacity of formulas between high - intake salt individuals from low - intake individuals, taking the arbitrary values 3000 and 3900 mg/ day for, respectively, Na and K intake. Formulas produced significant mean bias for UNa: Kawasaki -1277, INTERSALT -569, NHANES -116 and for UK Tanaka -754, Kawasaki -95 mg/ day. Correlation coefficients were less than 0.360 and ICC coefficients were all less than 0.458 for both UNa and UK estimations. Bias varied across quintiles with overestimation of UNa at lower quintiles (by 29-105%) and underestimation at higher quintile (by 7-37%) regardless of formula. The Bland-Altman plots indicated a high dispersion of the estimates biases regardless of the formulae and normotension / hypertension condition particularly at higher levels. All formulas exhibited an area under the receiver operating characteristic curve below 0.67 both in normotensive individuals and hypertensive individuals. We found a poor agreement between estimated and observed measurements of UNa and UK in our large population. All these formulas incur in over - or underestimations of UNa and UK excretion that may be unreliable for clinical evaluation of individual's and mean population daily UNa and UK excretion.
27898506	14	26	populational	T098	UMLS:C1257890
27898506	51	60	potassium	T103	UMLS:C1971990
27898506	61	70	excretion	T038	UMLS:C0221102
27898506	81	94	urine samples	T031	UMLS:C1610733
27898506	81	94	urine samples	T031	UMLS:C1610733
27898506	115	123	formulas	T170	UMLS:C0282574
27898506	144	158	representative	T098	UMLS:C1257890
27898506	159	169	population	T098	UMLS:C1257890
27898506	186	191	study	T062	UMLS:C2603343
27898506	270	287	urinary potassium	T103	UMLS:C1971990
27898506	289	291	UK	T103	UMLS:C1971990
27898506	293	302	excretion	T038	UMLS:C0221102
27898506	325	333	formulae	T170	UMLS:C0282574
27898506	354	367	urine samples	T031	UMLS:C1610733
27898506	386	397	individuals	T098	UMLS:C0237401
27898506	432	447	representatives	T098	UMLS:C1257890
27898506	451	472	Portuguese population	T098	UMLS:C0032730
27898506	474	480	Tanaka	T170	UMLS:C0282574
27898506	482	490	Kawasaki	T170	UMLS:C0282574
27898506	492	501	INTERSALT	T170	UMLS:C0282574
27898506	506	521	NHANES formulae	T170	UMLS:C0282574
27898506	556	558	UK	T103	UMLS:C1971990
27898506	559	568	excretion	T038	UMLS:C0221102
27898506	589	604	urinary samples	T031	UMLS:C1610733
27898506	653	666	urine samples	T031	UMLS:C1610733
27898506	711	713	UK	T103	UMLS:C1971990
27898506	838	840	UK	T103	UMLS:C1971990
27898506	1010	1012	Na	T103	UMLS:C0037473
27898506	1017	1018	K	T103	UMLS:C0032821
27898506	1019	1028	excretion	T038	UMLS:C0221102
27898506	1036	1045	subgroups	T170	UMLS:C1515021
27898506	1079	1081	Na	T103	UMLS:C0037473
27898506	1086	1087	K	T103	UMLS:C0032821
27898506	1088	1097	excretion	T038	UMLS:C0221102
27898506	1102	1111	subgroups	T170	UMLS:C1515021
27898506	1120	1139	hypertension status	T033	UMLS:C0586110
27898506	1232	1240	formulas	T170	UMLS:C0282574
27898506	1263	1267	salt	T103	UMLS:C0036140
27898506	1268	1279	individuals	T098	UMLS:C0237401
27898506	1298	1309	individuals	T098	UMLS:C0237401
27898506	1380	1382	Na	T103	UMLS:C0037473
27898506	1387	1388	K	T103	UMLS:C0032821
27898506	1397	1405	Formulas	T170	UMLS:C0282574
27898506	1446	1454	Kawasaki	T170	UMLS:C0282574
27898506	1462	1471	INTERSALT	T170	UMLS:C0282574
27898506	1478	1484	NHANES	T170	UMLS:C0282574
27898506	1498	1500	UK	T103	UMLS:C1971990
27898506	1501	1507	Tanaka	T170	UMLS:C0282574
27898506	1514	1522	Kawasaki	T170	UMLS:C0282574
27898506	1645	1647	UK	T103	UMLS:C1971990
27898506	1813	1820	formula	T170	UMLS:C0282574
27898506	1862	1872	dispersion	T082	UMLS:C0332624
27898506	1915	1923	formulae	T170	UMLS:C0282574
27898506	1928	1940	normotension	T033	UMLS:C0243095
27898506	1943	1955	hypertension	T038	UMLS:C0020538
27898506	2001	2009	formulas	T170	UMLS:C0282574
27898506	2097	2109	normotensive	T033	UMLS:C0243095
27898506	2110	2121	individuals	T098	UMLS:C0237401
27898506	2126	2138	hypertensive	T033	UMLS:C0857121
27898506	2139	2150	individuals	T098	UMLS:C0237401
27898506	2233	2235	UK	T103	UMLS:C1971990
27898506	2249	2259	population	T098	UMLS:C1257890
27898506	2271	2279	formulas	T170	UMLS:C0282574
27898506	2327	2329	UK	T103	UMLS:C1971990
27898506	2330	2339	excretion	T038	UMLS:C0221102
27898506	2367	2386	clinical evaluation	T058	UMLS:C4084924
27898506	2390	2402	individual's	T098	UMLS:C0237401
27898506	2437	2439	UK	T103	UMLS:C1971990
27898506	2440	2449	excretion	T038	UMLS:C0221102